Celltrion Healthcare: New Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma

Press/Media: Press / Media

Period2020 Jun 14

Media coverage

1

Media coverage

  • TitleCelltrion Healthcare: New Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date20/6/14
    PersonsKi woo Kim